Sponsored by Boehringer-Ingelheim (Golin)

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Overview

The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose-lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.

Speaker(s)

Davida F. Kruger, MSN, APN-BC, BC-ADM

  Certified Nurse Practitioner; Henry Ford Health System
  Division of Endocrinology, Diabetes, Bone and Mineral Disease; New Center One
  Detroit, MI

Sponsored by Vindico Medical Education

Overview

Influenza or COVID-19? Dr. Charles Vega and Dr. Ruth Carrico will discuss the optimal ways to diagnose and treat influenza during the COVID-19 pandemic.

Learning Objectives

Upon successful completion of the activities, participants will be able to:
• Utilize appropriate diagnostic tools that can differentiate and detect influenza early in its course.
• Incorporate the use of antiviral treatment in patients with influenza based upon efficacy, safety, and propensity for resistance in those who are at normal or high risk for complications.

Course Summary

Speaker(s)

Ruth Carrico, Ph.D., DNP, APRN, CIC, FSHEA, FNAP

  Professor, University of Louisville School of Medicine, Division of Infectious Disease

Charles P. Vega, MD, FAAFP 

  Health Sciences Clinical Professor, Department of Family Medicine

  Director, Program in Medical Education for the Latino Community

  Assistant Dean for Culture and Community Education, University of California, Irvine

Sponsored by PCEC

This presentation supported by an educational grant from AstraZeneca Pharmaceuticals LP

Overview

The management of patients with suspected chronic kidney disease (CKD) involves numerous clinical decisions beginning with considerations for screening and extending through optimal treatment. This activity explores many of these clinical questions encountered by primary care clinicians, with discussion about 2020 guidelines issued by Kidney Disease – Improving Global Outcomes (KDIGO) and the American Diabetes Association (ADA). While renin-angiotensin-aldosterone (RAAS) inhibitor therapy is well established in the treatment of patients with CKD, the sodium glucose cotransporter-2 (SGLT-2) inhibitors are quickly assuming an important role in these patients, with as well as without diabetes mellitus. Clinical questions related to the use of the SGLT-2 inhibitors in patients with CKD are discussed amidst the growing evidence supporting their important role.

Learning Objectives

At the end of the activity, participants will be able to:

• Identify the risks and consequences of chronic kidney disease.
• Screen appropriately for the presence of CKD in patients at high risk.
• Describe the safety and efficacy of SGLT2 inhibitors on renal outcomes in patients with and without type 2 diabetes mellitus.
• Initiate evidence-based therapy for lowering blood glucose in patients with established kidney disease as recommended in updated guidelines.

Course Summary

Speaker(s)

Stephen Brunton, MD, FAAFP

  Adjunct Associate Professor

  Touro University California, College of Osteopathic Medicine

Sponsored by Boehringer-Ingelheim (VMLY&R)

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Overview 

Join Dr. Michael Zlupko as he provides an overview of common interstitial lung diseases (ILDs) and reviews the signs and symptoms of disease progression. Dr. Zlupko will also highlight the significance of comprehensive care for patients with ILD.

Learning Objectives

 Upon completion of this session, participants should be able to:
• Provide an overview of common ILDs and the impact of these ILDs on patients
• Improve the identification of patients with potential ILDs in order to support a timely and accurate diagnosis
• Develop a comprehensive care strategy for patients with ILD

Speaker(s)

Michael C. Zlupko, MD

 Altoona Lung Specialists

 Altoona, PA

Sponsored by Takeda

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Speaker(s)

TBD

Sponsored by DKB Med.  Grant support for this program is provided by Regeneron.

Learning Objectives

• Describe current management strategies and identify potential treatments for mild to moderate COVID-19, with a specific focus on vulnerable populations
• Evaluate best practices for managing patients with COVID-19 using monoclonal antibodies and other agents, with a focus on efficacy against emerging viral variants.
• Clinicians require education about treating people with COVID-19 requiring hospitalization.
• Describe current management strategies and identify potential treatments for COVID-19 requiring hospitalization.

Course Summary

Speaker(s)

Charles P. Vega, MD, FAAFP

  Health Sciences Clinical Professor, UC Irvine Department of Family Medicine

  Assistant Dean for Culture and Community Education, UC Irvine School of Medicine

  Director, UC Irvine Program in Medical Education for the Latino Community, Irvine, CA

Sponsored by AstraZeneca

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Learning Objectives

As a result of this activity, learners will be able to:

1. Describe the Progressive nature of CKD leading to significant morbidity and mortality.

2. Discuss the disease burden of CKD and the importance of screening and diagnosis.

3. SGTL2i as recommended part of initial therapy in patients with T2D and CKD.

4. Overview of DAPA-CKD trial and trial endpoints.

Speaker(s)

Alisha Allen, PA-C 

This presentation will cover the common issue of burnout and the epidemic of self-induced disease. Importantly, the speaker will discuss a doable strategy on how we can all get on a path of greater well-being by implementing key elements.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Describe the 10 leading diagnoses on death certificates and the underlying causes of these diseases
2. Discuss mainstream areas of research that are focusing on underlying causes of disease and prevention strategies
3. Understand essential elements to health and happiness and keys to implementation

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Patricia J. Sulak, MD

 Founder, Living WELL Aware LLC

 Professor, Texas A&M College of Medicine; Gynecologist, Baylor Scott & White Health

Nurse Practitioners are on the front line in the role of treating adults with Type 2 Diabetes Mellitus. According to the CDC, more than 34 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more often teens and young adults are also developing it.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Understand ADA and AACE guidelines and how they pertain to medication treatment options
2. Review antidiabetic treatment options; pro’s, con’s and costs
3. Apply the knowledge learned in multiple case studies such that the learner is comfortable with newer standards and how they may apply

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Gary Graf, MSN, ARNP-C

 Family Nurse Practitioner (BC)

 Cotton-O'Neil Diabetes and Endocrinology Center

Common musculoskeletal primary care complaints involve low back, hip, shoulder, or knee pain. In this session, the learner will develop a greater understanding and confidence in discerning between common differential diagnoses for these regional musculoskeletal pain complaints. Additionally, the learner will be able to formulate an initial treatment approach to these common primary care musculoskeletal conditions.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. List the elements of the history that differentiate between various common MSK causes of regional pain
2. Describe the distinguishing features found on examination for various common MSK causes of regional pain
3. List the key treatments for common MSK causes of regional pain

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Michael E. Zychowicz, DNP, ANP, ONP, FAAN, FAANP

 Professor & Lead Faculty, Orthopedic NP Specialty

 Duke University School of Nursing

Sponsored by Novo Nordisk

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Overview

Explore efficacy and safety data for 2 GLP-1 RA options for adults with T2D. A data review from select pivotal glycemic control trials as well as cardiovascular outcomes data will be presented.

Speaker(s)

Lucia M. Novak, MSN, ANP-BC, BC-ADM

  President and Owner, Diabetes Consulting Services, North Bethesda, Maryland
  Co-Executive Director, Capital Health & Metabolic Center of Capital Diabetes & Endocrine Associates, Camp Springs and Silver Spring, Maryland

As the demand for facial rejuvenation increases, advances in medically-based, non-surgical treatments provide more options than ever before. The increasing use of facial injectables, such as botulinum toxin and facial fillers are major factors driving the aesthetic medicine market. This presentation will focus on these injectables to achieve the best possible esthetic and therapeutic outcomes. An understanding of facial anatomy, the aging process, and safety issues for injectable therapy is needed to diagnose and recommend aesthetic treatment plans. A review of neurotoxins and dermal fillers, including the mechanism of action, side effects, expected results, and complications with protocols will be discussed. The goal is to learn the foundational integration of neurotoxin and dermal filler therapy into practice.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Report common characteristics of facial aging
2. Compare and contrast aesthetic injectable products with safe facial application areas
3. State complications of injectables and what to do when things go wrong.

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Marianne Woody MSN, APRN-BC, DCNP, CANS

 Nurse Practitioner

 Juva Skin and Laser; Aestique Plastic Surgery; MediSpa

The Nurse Practitioner in the Primary Care setting is challenged in the treatment of ASCVD to provide the most up-to-date goals, treatment guidelines, and expectations for primary vs secondary prevention. This program will sift through the complicated updates of the past few years and allow the nurse practitioner to incorporate these into their practice.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Determine a risk assessment and appropriate goals for ASCVD to the adult population
2. Review and examine the treatment modalities and pathophysiology for cholesterol management
3. Develop treatment plans to appropriately treat adults with dyslipidemia

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Gary Graf, MSN, ARNP-C

 Family Nurse Practitioner (BC)

 Cotton-O'Neil Diabetes and Endocrinology Center

Sponsored by AstraZeneca

This program is not accredited for Continuing Education credit. This program is designated as Non-CE programs and contact hours will not be awarded.

Learning Objectives

• Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
• Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
• Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

Speaker(s)

Victor Howard, MD, FACC

This is a seated therapeutic class so there is no need for special yoga clothing or gear. This way of practicing yoga was studied during the early phases of the pandemic in 2020. After eight 1-hour sessions, results indicated statistical significance in reducing four types of symptoms (PTSD, anxiety, depression, insomnia) in health professionals.

Presented by

Jay Gupta, RPh, MSc, MTM Consultant, C-IAYT

 President

 RxRelax

Updates to the 2007 NAEPP/NHLBI asthma guidelines were published in late 2020. These updates cover five specific areas of asthma evaluation and management but leave many areas without updates. To fill in those gaps, many clinicians use the GINA guidelines produced in the UK. In this presentation, the new NAEPP/NHLBI updates will be reviewed and compared to older recommendations and to the broader recommendations from GINA. By including both sets of guidelines, the full spectrum of asthma diagnosis, evaluation and management can be reviewed.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Incorporate the 2020 NAEPP updates to the 2007 asthma guidelines.
2. Compare recommendations from 2020 NAEPP with the broader international GINA asthma guidelines.
3. Incorporate tools into practice that support guideline-concordant asthma care.

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Barbara P. Yawn, MD, MSc, MSPH, FAAFP

 Adjunct Professor

 University of Minnesota Family and Community Health

This presentation will review the newest options and recommendations for contraceptive management. We will cover newly available methods as well as those more established. The presentation will also cover strategies to improve contraception adherence including common mistakes patients make and how to address them.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Detail the new contraceptive methods available in the last year.
2. Review the different strategies available to improve patient satisfaction with their contraceptive method.
3. Provide accurate information about the efficacy and use of common contraceptive methods.

Course Summary

Virtual Conference Platform

Go to Virtual Conference Platform

Alison O. Marshall, RN, MSN, FNP-C

 Faculty, Sylvie Ratelle STD/HIV Prevention Center of New England

 Clinical Instructor, Boston College Connell School of Nursing

Sponsored by PCEC.  This presentation supported by an educational grant from GlaxoSmithKline.

Overview

About one out of three people in the United States will develop shingles in their lifetime. Annually, approximately one million people develop shingles. The pain caused by shingles results in significant patient morbidity, generally lasting a few weeks, although postherpetic neuralgia can persist long term. Although less common, shingles may lead to serious complications involving the eye, lungs, and brain. This presentation is designed to help clinicians educate their patients about the disease and the importance of vaccination.

Learning Objectives

•  Utilize available resources to increase awareness among patients about the importance and safety of recommended vaccinations.
•  Characterize the burden of herpes zoster infections.
•  Prescribe the recombinant herpes zoster vaccine as described in ACIP recommendations.
•  Implement strategies to increase patient acceptance of herpes zoster and other vaccinations.

Course Summary

Speaker(s)

Wendy L. Wright DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

  Owner and Adult/Family Nurse Practitioner

  Wright & Associates Family Healthcare

This presentation will review common tremor types seen in primary care. A discussion on specific tremor characteristics will review the relevant history and physical examination findings seen in enhanced physiologic, essential, parkinsonism, and psychogenic tremor disorders. Pharmacologic and non-pharmacologic treatment options will be presented along with other evidence-based approaches to these movement disorders.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Recognize and discuss differentials of common tremor types and disorders that are seen in primary care.
2. Identify the specific pertinent history questions and physical examination findings commonly seen in tremor disorders.
3. Discuss pharmacological and non-pharmacological treatment options for common tremor disorders in primary care. 

Course Summary

Virtual Conference Platform 

Go to Virtual Conference Platform

Amy Bruno, PhD, ANP-BC

 Primary Care Provider; Galileo Health

 Lecturer; MGH Institute of Health Professions School of Nursing

This presentation is intended as a review of proper procedural techniques associated with the female pelvic exam.  Pre-exam preparation, physical assessment skills, and common cervical appearances will be discussed.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Details the correct positioning and pre-pelvic exam preparation recommended for a successful examination.
2. Recognize common, normal variations in the appearance of the cervix.
3. List the proper order of physical examination steps to complete the pelvic exam.

Course Summary

Virtual Conference Platform 

Go to Virtual Conference Platform

Alison O. Marshall, RN, MSN, FNP-C

 Faculty, Sylvie Ratelle STD/HIV Prevention Center of New England

 Clinical Instructor, Boston College Connell School of Nursing

This session examines polypharmacy trends and implications. It describes what is currently being done and explores additional prospective solutions.  A list of resources is provided to help empower nurse practitioners to consider and incorporate principles of mindful prescribing.

Learning Objectives

After taking part in this educational activity, participants should be better able to:

1. Understand the incidence and determinants of polypharmacy 
2. Explore the implications of polypharmacy
3. Apply DePrescription interventions where appropriate
4. Prevent polypharmacy where possible

Course Summary

Virtual Conference Platform 

Go to Virtual Conference Platform

Jay Gupta, RPh, MSc, MTM Consultant, C-IAYT

 President

 RxRelax